Phase I trial combining chemokine-targeting with loco-regional chemo-immunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity

Overview of attention for article published in Clinical Cancer Research, January 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 33 news outlets

twitter: 8 X users

Citations

dimensions_citation: 19 Dimensions

Readers on

mendeley: 18 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 10 X posts from 8 X users, with an upper bound of 65,242 followers.

Phase 1 Study: Intraperitoneal Chemokine Modulation in Ovarian Cancer. https://t.co/zicXtOWWFO https://t.co/yi9AbavndQ

24 May 2022

Reply Repost Favourite

The authors of "Phase I trial combining chemokine-targeting with l…" (https://t.co/Huvh4vMvbx) included RRIDs in their paper! RRIDs like this improve reproducibility in scientific research. #STMpublishing #methodsmatter

15 May 2022

Reply Repost Favourite

Phase I trial by Orr et al shows that chemokine-modulating intraperitoneal chemo-immunotherapy combination is safe and tolerable in patients with epithelial #OvarianCancer and will be tested in a phase II trial. https://t.co/2O8trYGf81 https://t.co/jTvS7B

18 Feb 2022

Reply Repost Favourite

RT @NatRevClinOncol: In a phase I trial in 12 pts with epithelial ovarian cancer, cisplatin plus the TLR3 ligand rintatolimod and the COX-2…

02 Feb 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 6 additional X posts.